IPH5201 / AstraZeneca, Innate - LARVOL DELTA

IPH5201, an anti-CD39 monoclonal antibody, as monotherapy or in combination with durvalumab in advanced solid tumors. (PubMed, Cancer Res Commun) - "IPH5201 as monotherapy, or in combination with durvalumab, was well tolerated at pharmacologically active doses that induced reduction of intratumoral CD39 enzymatic activity and showed preliminary evidence for disease stabilization."

Journal • Monotherapy • Fatigue • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Cancer • Solid Tumor • ENTPD1

Innate Pharma Reports First Half 2024 Business Update and Financial Results (Businesswire) - "R&D expenses decreased by €2.4m to €29.1m in the first half of 2024 (€31.5m in the first half of 2023). This change is mainly explained by lower personnel and other R&D expenses by €2.2millions (-15.4%). This decrease is due to an non-recurring amortization charge in the first half of 2023, related to the IPH5201 rights (full amortization of the additional €2.0 million invoice from Orega Biotech following the dosing of the first patient in the Phase 2 MATISSE clinical trial in June 2023)."

Commercial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

INNATE PHARMA REPORTS FIRST QUARTER 2024 BUSINESS UPDATE AND FINANCIAL RESULTS (Innate Pharma Press Release) - "Top-line results in MF patients will be presented at the ASCO Annual Meeting 2024 being held May 31 – June 4 in Chicago...The full abstract will be released at 5:00 PM ET on Thursday, May 23, 2024 on the ASCO Annual Meeting website...The Phase 2 KILT (anti-KIR in T Cell Lymphoma) trial, an investigator-sponsored, randomized controlled trial led by the Lymphoma Study Association (LYSA) to evaluate lacutamab in combination with chemotherapy GEMOX (gemcitabine in combination with oxaliplatin) versus GEMOX alone in patients with KIR3DL2-expressing relapsed/refractory PTCL is ongoing and continues to recruit patients...The MATISSE Phase 2 clinical trial conducted by Innate in neoadjuvant lung cancer for IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, is ongoing and recruitment is on track."

P2 data • Trial status • Hematological Malignancies • Lung Cancer • Non-Hodgkin’s Lymphoma • Oncology • Peripheral T-cell Lymphoma • Solid Tumor • T Cell Non-Hodgkin Lymphoma

Innate Pharma Reports Third Quarter 2023 Financial Results and Business Update (Businesswire) - "SAR’514/IPH6401: The Phase 1/2 clinical trial with SAR’514 / IPH6401, a trifunctional anti-BCMA Nkp46xCD16 NK cell engager, led by Sanofi, in patients with Relapsed/Refractory Multiple Myeloma (RRMM) and Relapsed/Refractory Light-chain Amyloidosis (RRLCA) is ongoing....IPH6501 (proprietary): Following approval of the IND-filing by the FDA in July 2023, IPH6501, Innate’s proprietary CD20 targeted tetra-specific ANKET® continues toward a Phase 1 clinical trial in 2023....The MATISSE Phase 2 clinical trial conducted by Innate in neoadjuvant lung cancer for IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, is ongoing and recruitment is on track....The investigator-sponsored CHANCES Phase 1 trial of IPH5301 by Institut Paoli-Calmettes is ongoing."

Enrollment status • Trial status • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lung Cancer • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Solid Tumor

A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell lung cancer (MATISSE) (ESMO 2023) - P2 | "Assessment of exploratory biomarkers is also planned. A Safety Review Committee will conduct evaluations on an ongoing basis and two interim analyses will be performed."

Clinical • IO biomarker • P2 data • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ENTPD1

Innate Pharma Announces Abstracts Selected for ESMO Congress 2023 (Businesswire) - "Innate Pharma SA...announced that the following presentations will be presented at the European Society for Medical Oncology (ESMO) Congress 2023, taking place October 20-24 in Madrid, Spain."

P2 data • P3 data • PK/PD data • Trial status • Acute Myelogenous Leukemia • B Acute Lymphoblastic Leukemia • Head and Neck Cancer • Hematological Malignancies • Leukemia • Lung Cancer • Myelodysplastic Syndrome • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma of Head and Neck

Innate Pharma Reports First Half 2023 Financial Results and Business Update (Businesswire) - "Revenue from collaboration and licensing agreements for monalizumab decreased by €6.9m to €9.5m in the first half of 2023 (€16.4m in the first half of 2022). This change mainly results from the transaction price increase of €13.4 million ($14.0 million) in the first half of 2022, triggered by the launch of the 'PACIFIC-9' Phase 3 trial on April 28, 2022....R&D expenses from continuing operations increased by €6.5m to €31.5m in the first half of 2023 (€25.0m in the first half of 2022)....This increase is mainly explained by €2.0m amortization for the rights relating to IPH5201 following the first patient dosed in the Phase 2 MATISSE clinical trial. The amortization of rights related to the monalizumab decreased by €0.3m."

Commercial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Thoracic Cancer

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Innate Pharma | Initiation date: Feb 2023 ➔ Jun 2023

Trial initiation date • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • PD-L1

First Patient Dosed in Phase 2 MATISSE Trial of IPH5201 in Early Stage Lung Cancer (Businesswire) - "Innate Pharma SA...announced the first patient was dosed in MATISSE, a Phase 2 multicenter single-arm study (NCT05742607), sponsored by Innate Pharma, evaluating neoadjuvant and adjuvant treatment with IPH5201, an anti-CD39 blocking monoclonal antibody, in combination with durvalumab (anti-PD-L1) and chemotherapy, in treatment-naïve patients with resectable early stage non-small cell lung cancer (NSCLC)."

Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Innate Pharma Reports First Quarter 2023 Financial Results and Business Update (Businesswire) - "IPH6501 continues toward a Phase 1 clinical trial in 2023 for the proprietary CD20 targeted tetra-specific ANKET®; Innate continues to see progress for monalizumab in the early non-small cell lung cancer (NSCLC) setting, with the ongoing Phase 3 PACIFIC-9 study run by AstraZeneca; Two monalizumab abstracts have been accepted for 'Trial in progress' posters at the American Society for Clinical Oncology (ASCO) 2023 Annual Meeting, taking place June 2-6, 2023 in Chicago, IL; The MATISSE Phase 2 clinical trial conducted by Innate in neoadjuvant lung cancer for IPH5201...has started and is awaiting first patient dosed; The investigator-sponsored CHANCES Phase 1 trial of IPH5301, in collaboration with Institut Paoli-Calmettes is ongoing."

New P1 trial • Trial status • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

Combination of IPH5201, a blocking antibody targeting the CD39 immunosuppressive pathway, with durvalumab and chemotherapies: Preclinical rationale (ESMO-IO 2022) - P1 | "Targeting the Ado pathway has recently been reported to improve Durvalumab (D) efficacy in early-stage NSCLC patients, through the use of Oleclumab, an anti-CD73 mAb...Finally, in vivo, in a mouse tumor model engrafted in huCD39KI mice, moIPH5201 improved the anti-tumor efficacy of gemcitabine and anti-PD-L1 combination. Conclusions IPH5201 was shown to block CD39 enzymatic activity, to lower Ado and increase ATP levels in the TME and finally to improve anti-tumor efficacy in preclinical models. Altogether, the expression profile of CD39 in early stage NSCLC and preclinical combination data support the clinical evaluation of IPH5201 in combination with D and CT in early stage NSCLC patients."

IO biomarker • Preclinical • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Squamous Cell Carcinoma • ENTPD1

IPH5201 as Monotherapy or in Combination with Durvalumab (D) in Advanced Solid Tumours (ESMO-IO 2022) - P1 | "Conclusions IPH5201 was well tolerated when used alone or in combination with D, with no new safety signals identified. PD were consistent with the mechanism of action."

Combination therapy • Monotherapy • Oncology • Solid Tumor • ENTPD1

IPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE) (clinicaltrials.gov) - P2 | N=70 | Recruiting | Sponsor: Innate Pharma

New P2 trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • ALK • PD-L1

Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 (Businesswire) - "Innate Pharma SA...announced that three posters showcasing IPH5201 and IPH5301 will be presented on December 8 at the 2022 European Society for Medical Oncology I-O (ESMO Immuno-Oncology) Annual Congress in Geneva, Switzerland....A Phase 2 clinical trial conducted by Innate in lung cancer is in planning."

P1 data • Preclinical • Trial status • Breast Cancer • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Gynecologic Cancers • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Solid Tumor

"$IPHA Innate Pharma to present adenosine franchise, IPH5201 and IPH5301 at ESMO IO 2022 https://t.co/WOSFWBcn5I" (@stock_titan)

Innate Pharma Reports Third Quarter Financial Results (Businesswire) - "Progress continues toward investigational new drug (IND) filing in 2023 for the CD20 targeted tetra-specific ANKET, IPH6501....The previously announced Phase 2 clinical trial conducted by Innate in lung cancer for IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca, is in planning. The Company will present a poster of preclinical data supporting the rationale for the clinical trial at the 2022 ESMO Immuno-Oncology (IO) Annual Congress in December."

IND • Preclinical • Lung Cancer • Oncology • Solid Tumor

"$SURF "pausing" development of SRF617 (anti-CD39 MAb), relevant for Tizona $ABBV (TTX-030), $IPH $AZN (IPH5201) & $GILD $RCUS (AB598)" (@JacobPlieth)

ENTPD1

"ph2 data expected in 2024 for IPH5201" (@LHC_21)

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=57 | Completed | Sponsor: MedImmune LLC | Active, not recruiting ➔ Completed

Combination therapy • Monotherapy • Trial completion • Oncology • Solid Tumor

IPH5201: Data from P1 trial (NCT04261075) for advanced solid tumors in H2 2022 (AstraZeneca) - H1 2022 Results

P1 data • Oncology • Solid Tumor

Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer (Businesswire) - "Innate Pharma SA...announced that IPH5201, an anti-CD39 blocking monoclonal antibody developed in collaboration with AstraZeneca...will advance into a Phase 2 clinical trial in lung cancer. Innate will receive a $5M milestone payment from AstraZeneca and will be responsible for conducting the study. AstraZeneca and Innate will share study costs and AstraZeneca will supply clinical trial drugs....'The decision to advance IPH5201...which also includes two Phase 3 trials with monalizumab in non-small cell lung cancer and head and neck cancer'....AstraZeneca conducted a Phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab (PD-L1). The data are expected to be presented at an upcoming medical meeting in due course."

Licensing / partnership • New P2 trial • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor

IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors. (clinicaltrials.gov) - P1 | N=57 | Active, not recruiting | Sponsor: MedImmune LLC | Trial completion date: Mar 2023 ➔ Jul 2022 | Trial primary completion date: Mar 2023 ➔ Jul 2022

Combination therapy • Monotherapy • Trial completion date • Trial primary completion date • Oncology • Solid Tumor

Innate Pharma Reports Full Year 2021 Financial Results and Business Update (Businesswire) - "IPH5201 (anti-CD39), partnered with AstraZeneca: AstraZeneca is conducting a Phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab (anti-PD-L1). The data is expected to be presented in 2023."

P1 data • Oncology • Solid Tumor

Innate Pharma presents its financial results and the progress of its portfolio for the year 2021 (Businesswire) - "AstraZeneca is conducting a Phase 1 trial in solid tumors with IPH5201 alone or in combination with durvalumab (anti-PD-L1) with data expected in 2023."

P1 data • Oncology • Solid Tumor

IPH5201: Data from P1 trial (NCT04261075) for advanced solid tumors in 2023 (AstraZeneca) - FY2021 Results

P1 data • Oncology • Solid Tumor